A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Clinical trial NCT05394116 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05394116
- Sponsor
- Regeneron Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-21
- Primary completion
- 2025-07-17
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.